▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #875 by analyst upside · 2026-09-28
OBIO
Orchestra BioMed Holdings, Inc.
Healthcare · Market Cap $358M · P/E 0x
ANALYST PRICE TARGET
+104.1%
implied upside to consensus target
Current Price $5.95
Consensus Target $12.14
Bull Target $20.0
Bear Target $9.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
0
Sell
0
52-Week Low $2.4
52-Week High $6.48
YTD Return +38.1%
FUNDAMENTALS
Market Cap $358M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $32M
Profit Margin -184.6%
52-WEEK RANGE
52-Week Low $2.4
52-Week High $6.48
Current Price $5.95
Bear Target $9.0
Bull Target $20.0
● Now $5.95 ● Target $12.14
TRADING DATA
Avg Volume 306K
YTD Return +38.1%
Analyst Count 7
Consensus Buy
Upside to Target +104.1%
Last Updated 2026-09-28

ANALYST SUMMARY

Orchestra BioMed Holdings, Inc. (OBIO) is currently trading at $5.95 with a Wall Street consensus price target of $12.14, implying potential upside of 104.1% over the next 12 months. 7 analysts currently cover OBIO, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $9.0.

OBIO operates in the Healthcare sector with a market capitalisation of $358M. The stock is up 38.1% year-to-date and is currently trading near the upper end of its 52-week range of $2.4 – $6.48.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OBIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B. Riley Securities - Reiterated
Buy → Buy 2026-09-15 17% win rate (6 calls)
BTIG ↑ Upgrade
Neutral → Buy 2026-09-10 38% win rate (8 calls)
Piper Sandler reit
Overweight → Overweight 2026-08-11 14% win rate (7 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-05-19 17% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-14 31% win rate (48 calls)
Barclays - Reiterated
Overweight → Overweight 2026-05-13 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-12 33% win rate (6 calls)
Barclays - Reiterated
Overweight → Overweight 2026-01-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →